Docusate Sodium — Class II drug recall D-1007-2019
Terminated recall by Rx Pak Division of McKesson Corporation, reported 2019-03-27, distributed nationwide. Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg s
| Recall number | D-1007-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Rx Pak Division of McKesson Corporation, Memphis, TN, United States |
| Recall initiated | 2019-01-16 |
| Classified | 2019-03-15 |
| Reported by FDA | 2019-03-27 |
| Terminated | 2020-12-02 |
| Distributed | Nationwide (US) |
| Quantity | 29,622 blister |
| Reason classes | labeling |
| NDC | 63739-0478-10 |
| Lot numbers | 0119397 |
| Expiration dates | 2020-02 |
Product
Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10
Reason for recall
Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1007-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.